Evidence map›Paper›PMID 33909133›Full record

ArticleEuropean radiology2021

Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy.

Qinmei Xu, Zeyu Sun, Xiuli Li, Chen Ye, Changsheng Zhou, Longjiang Zhang, Guangming Lu

Open access · hybridAbstract read
In one paragraph

Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Clinical-radiomic prognostic model integrating staging before and after neoadjuvant chemotherapy in gastric cancer: a multicenter retrospective study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Advancements in non-invasive diagnosis of gastric cancer.World journal of gastroenterology · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Qinmei XuDepartment of Medical Imaging, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, Jiangsu, China.
Zeyu SunDeepwise AI Lab, Deepwise Inc., No. 8 Haidian avenue, Sinosteel International Plaza, Beijing, 100080, China.
Xiuli LiDeepwise AI Lab, Deepwise Inc., No. 8 Haidian avenue, Sinosteel International Plaza, Beijing, 100080, China.
Chen YeResearch Institute of General Surgery, Jinling Hospital, Nanjing, 210002, Jiangsu, China.
Changsheng ZhouDepartment of Medical Imaging, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, Jiangsu, China.
Longjiang ZhangDepartment of Medical Imaging, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, Jiangsu, China.
Guangming LuDepartment of Medical Imaging, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, Jiangsu, China. cjr.luguangming@vip.163.com.ORCID http://orcid.org/0000-0003-4913-2314
Nanjing General Hospital of Nanjing Military Command · CNSinosteel (China) · CN

Funding

National Basic Research Program of China (973 Program) No.2014CB744504
6 · The paper itself

Abstract

objectivesTo develop and evaluate machine learning models using baseline and restaging computed tomography (CT) for predicting and early detecting pathological downstaging (pDS) with neoadjuvant chemotherapy in advanced gastric cancer (AGC).

methodsWe collected 292 AGC patients who received neoadjuvant chemotherapy. They were classified into (a) primary cohort (206 patients with 3-4 cycles chemotherapy) for model development and internal validation, (b) testing cohort I (46 patients with 3-4 cycles chemotherapy) for evaluating models' predictive ability before and after the complete course, and (c) testing cohort II (n = 40) for model evaluation on its performance at early treatment. We extracted 1,231 radiomics features from venous phase CT at baseline and restaging. We selected radiomics models based on 28 cross-combination models and measured the areas under the curve (AUC). Our prediction radiomics (PR) model is designed to predict pDS outcomes using baseline CT. Detection radiomics (DR) model is applied to restaging CT for early pDS detection.

resultsPR model achieved promising outcomes in two testing cohorts (AUC 0.750, p = .009 and AUC 0.889, p = .000). DR model also showed a good predictive ability (AUC 0.922, p = .000 and AUC 0.850, p = .000), outperforming the commonly used RECIST method (NRI 39.5% and NRI 35.4%). Furthermore, the improved DR model with averaging outcome scores of PR and DR models showed boosted results in two testing cohorts (AUC 0.961, p = .000 and AUC 0.921, p = .000).

conclusionsCT-based radiomics models perform well on prediction and early detection tasks of pDS and can potentially assist surgical decision-making in AGC patients. KEY POINTS: • Baseline contrast-enhanced computed tomography (CECT)-based radiomics features were predictive of pathological downstaging, allowing accurate identification of non-responders before therapy. • Restaging CECT-based radiomics features were predictive to achieve pDS after and even at an early stage of neoadjuvant chemotherapy. • Combination of baseline and restaging CECT-based radiomics features was promising for early detection and preoperative evaluation of pathological downstaging of AGC.

Indexed as

Neoadjuvant TherapyStomach NeoplasmsEarly Detection of CancerHumansRetrospective StudiesTomography, X-Ray ComputedDecision-makingGastric cancerMachine learningNeoadjuvant chemotherapy

Identifiers

PMID33909133
PMCPMC8523390
OpenAlexW3157289678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.